Alentis nabs $181M to broaden Claudin's scope in ADCs

Kyle LaHucik

Senior Reporter

Swiss biotech Alentis Therapeutics thinks it can expand the reach of the Claudin family in oncology, and half a dozen new investors are helping back …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Alentis nabs $181M to broaden Claudin's scope in ADCs

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Alen­tis nabs $181M to broad­en Claud­in's scope in AD­Cs

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Alentis nabs $181M to broaden Claudin's scope in ADCs